Advantage of dimeric peptide antigens in serodiagnosis of HIV-1 infection. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Advantage of dimeric peptide antigens in serodiagnosis of HIV-1 infection.

Microbiol Immunol. 1997;41(3):215-20. Unique Identifier : AIDSLINE MED/97276480
Gokulan K; Tripathi SP; Rao DN; Department of Biochemistry, All India Institute of Medical Sciences,; New Delhi, India.

Abstract: The reactivity of antibodies with dimeric and monomeric peptide antigens was compared by ELISA. A panel of highly purified synthetic peptides of HIV-1 representing defined regions, 598-609 and 524-533 (fusion domain) of gp41 and 306-320 of gp120, were used as antigens in the ELISA. These peptides were selected and synthesized taking into account the level of sequence conservation of various strains and hydrophilicity. The analysis included sera from 52 HIV-1 infected individuals and 53 HIV-1 negative controls. Both peptides from gp41 were found to be particularly immunoreactive with sera from HIV-1 infected individuals. The frequency of reactivity to the selected peptide from gp120 (V3 loop) in infected individuals was 82%. An interesting observation was that the dimeric peptide antigens had a detection rate more than 4-fold higher than the monomeric antigens. We found that lower levels of antibodies could be detected with dimeric antigens. The peptides reacted with few sera other than HIV-1 positive sera. These results implicate the potential dimeric peptide antigens to be utilized in the serodiagnosis of HIV-1 infection.
Keywords: *AIDS Serodiagnosis/METHODS *Gene Products, env/DIAGNOSTIC USE *HIV Antigens/DIAGNOSTIC USE *HIV Seropositivity/DIAGNOSIS *HIV-1/IMMUNOLOGY *Peptides/DIAGNOSTIC USEKWDaidsserodiagnosis/methodsKWDgeneproducts,env/diagnosticuseKWDhivantigens/diagnosticuseKWDhivseropositivity/diagnosisKWDhiv-1/immunologyKWDpeptides/diagnosticuse
970930
M9791302

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .